Clinical operations field note
How to Staff Phase 1 Oncology Trials
Evaluate Phase 1 oncology CTM and CRA readiness for dose escalation, evolving safety data, eligibility, and rapid protocol amendments.
By Lampgen Clinical Research
1 min read · estimated
- EARLY-PHASE WORK MOVES FAST Protocol amendments, dose decisions, and emerging safety information can change priorities quickly.
- COMMUNICATION IS PART OF RISK CONTROL Slow escalation between sites, vendors, and the sponsor can affect more than a timeline.
- EXPERIENCE MUST MATCH THE STUDY Years in clinical research do not automatically equal readiness for dose escalation or complex oncology eligibility.
- THE RIGHT RESOURCE REDUCES THE LEARNING CURVE Phase I programs need CTMs and CRAs who understand the pace, ambiguity, and documentation discipline.
Phase I oncology does not allow a long adjustment period.
Teams may be managing evolving safety information, narrow eligibility criteria, dose-escalation decisions, protocol amendments, intensive site communication, and incomplete data at the same time.
That environment changes the staffing question.
The question is not simply whether someone has worked as a CRA or CTM. It is whether that person can operate when the study is moving quickly and the information is still developing.
Phase I oncology staffing should account for dose-escalation schedules, time-sensitive pharmacokinetic sampling, and safety escalation.
For early-phase staffing, relevance matters as much as tenure.